Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK E803Q ALK V1180L |
Therapy | Alectinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK E803Q ALK V1180L | lung adenocarcinoma | predicted - resistant | Alectinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK E803Q and V1180L were identified in post-progression biopsy in a patient with metastatic lung adenocarcinoma harboring EML4-ALK (e6:e20), who previously achieved a partial response on Alecensa (alectinib) treatment (PMID: 39267820). | 39267820 |
PubMed Id | Reference Title | Details |
---|---|---|
(39267820) | A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review. | Full reference... |